Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
With a market cap of 82.57B, Regeneron(REGN) trades at $781.60. The stock has a price-to-earnings ratio of 18.32 and currently yields dividends of 47.1%.
On 2026-03-09, Regeneron(REGN) stock traded between a low of $741.98 and a high of $783.65. Shares are currently priced at $781.60, which is +5.3% above the low and -0.3% below the high.
The Regeneron(REGN)'s current trading volume is 678.59K, compared to an average daily volume of 668.11K.
During the past year, Regeneron(REGN) stock moved between $476.49 at its lowest and $821.11 at its peak.
During the past year, Regeneron(REGN) stock moved between $476.49 at its lowest and $821.11 at its peak.
REGN News
(RTTNews) - Regeneron Pharmaceuticals said olatorepatide, an investigational obesity treatment it licensed from Hansoh Pharmaceutical Group, delivered positive...
Regeneron Pharmaceuticals (REGN) said its partner Hansoh Pharma reported positive Phase 3 results for obesity drug olatorepatide in Chinese patients. The once-...
Regeneron Pharmaceuticals (REGN) announced Hansoh Pharmaceutical Group Company (HNSPF) has shared topline data from its Phase 3 trial in Chinese patients evalua...
Analyst ratings
73%
of 30 ratingsMore REGN News
Advertisement Regeneron Pharmaceuticals overview Regeneron Pharmaceuticals (REGN) has drawn investor attention after its shares closed at US$764.93, with rece...
Barclays initiated coverage of Regeneron (REGN) with an Overweight rating and $923 price target The shares are “fundamentally mispricing” the company’s profits...
Sanofi ( (SNY) ) has shared an update. On February 24, 2026, Sanofi and Regeneron secured U.S. FDA priority-review approval for Dupixent as the first and only...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.